New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
08:15 EDTNWBONorthwest's DCVax-Direct doesn't meet tumor response criteria, TheStreet says
None of 19 patients with advanced, metastatic cancers in an ongoing phase I trial have responded to treatment with Northwest Biotherapeutics' DCVax-Direct as defined by a standard known as RECIST, or Response Evaluation Criteria in Solid Tumors, which says partial response requires a 30% reduction in the size of the target lesion, according to TheStreet's Adam Feuerstein. Northwest's CEO Linda Powers said the greatest response seen so far after DCVax-Direct injections directly into a single tumor was a 28% reduction, according to Feuerstein. Reference Link
News For NWBO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
09:08 EDTNWBONorthwest Biotherapeutics begins first treatment with DCVax-L in Germany
Subscribe for More Information
October 7, 2014
09:07 EDTNWBONorthwest Biotherapeutics raises $11.5M through an institutional stock sale
Northwest Biotherapeutics announced that the Company has entered into an agreement with a single existing institutional shareholder for the purchase and sale of approximately $11.5M of newly issued shares of the Company's Common Stock at a price of $5.05 per share. H.C. Wainwright & Co., LLC acted as the sole placement agent for the transaction.
09:05 EDTNWBONorthwest Biotherapeutics enters into $11.5M financing agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use